A major new study has delivered what critics are calling the final collapse of the “transgender house of cards” — proving that puberty blockers, cross-sex hormones, and other medical interventions for gender-dysphoric minors do nothing to reduce psychiatric problems and appear to make them significantly worse.
The large Finnish register study, published earlier this month in the journal Acta Paediatrica, tracked gender-referred adolescents from 1996 to 2019. It found that these youth already suffered severe psychiatric morbidity long before any medical transition began. Before referral to gender clinics, 45.7% of the gender-dysphoric group required psychiatric treatment — compared to just 15% of matched controls.
More than two years after referral, the rate had risen to 61.7% for the gender-referred adolescents versus 14.6% for controls.Among those who actually received medical gender reassignment (cross-sex hormones or surgery), psychiatric needs increased sharply. For example, in the feminizing-treatment group, psychiatric morbidity jumped from 9.8% to 60.7%.The researchers’ conclusion was unambiguous: “Psychiatric needs do not subside” following the treatments.
Writing in National Review, endocrinologist Dr. Roy Eappen argues that the findings demolish the central justification for the child sex-change industry — the claim that these interventions are medically necessary and life-saving. Instead, the evidence shows they rest on falsehoods rather than science, violating core principles of medical ethics.The study arrives after the U.S. Supreme Court upheld Tennessee’s ban on transgender medical procedures for minors in 2025, further eroding the activist-driven model of “gender-affirming care.”
Discussion about this post